Predicting and preventing post-ERCP pancreatitis.
Pancreatitis is rightly the most feared complication of endoscopic retrograde cholangiopancreatography (ERCP). Ten percent to 15% of cases of post-ERCP pancreatitis (PEP) are severe by clinical and radiologic criteria. Such cases carry significant morbidity and mortality and are responsible for the vast majority of ERCP-related deaths. The prediction and prevention of PEP have been of great interest to endoscopists since the introduction of ERCP 30 years ago. Prediction and diagnosis of PEP have become more accurate with the widespread availability of serum amylase estimation. A variety of cytokines (eg, interleukin -1, IL-6, and IL-8) and acute phase reactants (eg, C-reactive protein) are also elevated in the serum in acute pancreatitis, and these form the basis of evolving tests for PEP. Urine testing (for amylase) in acute pancreatitis is obsolete, but it may soon undergo a revival in the form of a rapid (3-minute) dipstick test for trypsinogen-2, a sensitive and specific test for this disease. The prevention of PEP takes multiple forms. The following steps are recommended for clinicians: 1) avoid ERCP when other, less invasive or noninvasive imaging tests can do the job (eg, CT or magnetic resonance imaging); 2) avoid high-risk (of PEP) procedures, such as needle-knife papillotomy, balloon dilation of the biliary sphincter, and pancreatic sphincterotomy, and take steps to reduce risk when these procedures are unavoidable; 3) ensure that those who perform ERCP have adequate training and experience; and 4) consider pharmacologic intervention. Despite a depressing catalog of drug interventions that have failed over the years (eg, antihistamines, anticholinergics, and corticosteroids), three agents have recently shown promise: somatostatin; its octapeptide analogue, octreotide; and gabexate mesylate, a protease inhibitor.
Baillie
John
J
Division of Gastroenterology, Duke University Medical Center, Box 3189, Durham, NC 27710, USA. Baill001@mc.duke.edu
D000208:Acute Disease; D000209:Acute-Phase Proteins / Q000032:analysis; D000681:Amylases / Q000097:blood; D015415:Biomarkers / Q000032:analysis; D002116:Calcitonin / Q000097:blood; D002760:Cholangiopancreatography, Endoscopic Retrograde / Q000009:adverse effects* / Q000592:standards; D003287:Contrast Media; D016670:Gabexate / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D016753:Interleukin-10 / Q000627:therapeutic use; D007378:Interleukins / Q000097:blood; D015282:Octreotide / Q000627:therapeutic use; D010195:Pancreatitis / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control* / Q000628:therapy; D011498:Protein Precursors / Q000097:blood; D018570:Risk Assessment; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use; D013004:Somatostatin / Q000627:therapeutic use; D014362:Trypsinogen / Q000378:metabolism
D000209:Acute-Phase Proteins; D015415:Biomarkers; D003287:Contrast Media; D006728:Hormones; D007378:Interleukins; D011498:Protein Precursors; D015842:Serine Proteinase Inhibitors; D016753:Interleukin-10; D016670:Gabexate; D013004:Somatostatin; D014362:Trypsinogen; D002116:Calcitonin; D000681:Amylases; D015282:Octreotide